2024 Annual Meeting | C136 - Pediatric Vascular Neurology

Date Tuesday 04/16/24

Time 03:30 PM - 05:30 PM MDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Catherine M. Amlie-Lefond, MD, FAAN

Topic(s) Cerebrovascular Disease and Interventional Neurology, Child Neurology and Developmental Neurology

Learning Objectives Participants should gain an understanding of the unique aspects of cerebral sinus venous thrombosis in children; describe current use of genetic testing to inform care of vascular disorders in childhood; and recognize the importance pathophysiology in childhood stroke.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Program Level Advanced

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Case-based, Didactic

Event Timeline
03:30 PM - 03:35 PM MDT	Introduction	Introduction Catherine M. Amlie-Lefond, MD, FAAN
03:35 PM - 04:10 PM MDT	Speaker	Cerebral Sinus Venous Thrombosis Taryn-Leigh Surtees, MD
04:10 PM - 04:45 PM MDT	Speaker	Genetics of Pediatric Vascular Neurology Patricia Musolino, MD, PhD
04:45 PM - 05:20 PM MDT	Speaker	Childhood Arterial Ischemic Stroke—Beyond the Stroke Code Catherine M. Amlie-Lefond, MD, FAAN
05:20 PM - 05:30 PM MDT	Speaker	Questions & Answers Catherine M. Amlie-Lefond, MD, FAAN, Taryn-Leigh Surtees, MD, Patricia Musolino, MD, PhD

Faculty Disclosures
Catherine M. Amlie-Lefond, MD, FAAN	Dr. Amlie-Lefond has nothing to disclose.
Taryn-Leigh Surtees, MD	Dr. Surtees has nothing to disclose.
Patricia Musolino, MD, PhD	An immediate family member of Dr. Musolino has received personal compensation for serving as an employee of EMD Sorono. Dr. Musolino has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Minoryx Pharmaceuticals. Dr. Musolino has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for IONIS Pharmaceuticals . Dr. Musolino has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Inozyme Pharma. Dr. Musolino has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vertex Pharmaceuticals. An immediate family member of Dr. Musolino has or had stock in 2seventy Bio. An immediate family member of Dr. Musolino has or had stock in Editas Medicine. An immediate family member of Dr. Musolino has or had stock in Generation Bio. An immediate family member of Dr. Musolino has or had stock in Beam Therapeutics. An immediate family member of Dr. Musolino has or had stock in Ebotec . An immediate family member of Dr. Musolino has or had stock in Novonordisk. An immediate family member of Dr. Musolino has or had stock in Morphosys. The institution of Dr. Musolino has received research support from National Institute of Health-NINDS-R01. The institution of Dr. Musolino has received research support from Angea Biotherapeutics. The institution of Dr. Musolino has received research support from Minoryx Pharmaceuticals. The institution of Dr. Musolino has received research support from Belanger Foundation. The institution of Dr. Musolino has received research support from Rozwat Family Foundation. The institution of Dr. Musolino has received research support from Dooley Family Foundation. Dr. Musolino has received intellectual property interests from a discovery or technology relating to health care. Dr. Musolino has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��